<scp>CD33</scp>‐directed immunotherapy with third‐generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and<scp>CD33</scp>‐edited acute myeloid leukemia and hematopoietic stem and progenitor cells
International journal of cancer